Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome
- Resource Type
- Article
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia March 2023 23(3):e164-e170 - Subject
- Language
- ISSN
- 2152-2650